Publications by authors named "John S Tyhonas"

Claim this Profile
T
The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition.
Young K Chen, Toufike Kanouni, Lee D Arnold, Jason M Cox, Elisabeth Gardiner, John S Tyhonas

J Med Chem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations.
John S Tyhonas, Lee D Arnold, Jason M Cox, Aleksandra Franovic, Elisabeth Gardiner

J Med Chem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5(Z)-benzylidene-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-1-aza-6-oxa-chrysenes as non-steroidal glucocorticoid receptor modulators.
Robert J Ardecky, Andrew R Hudson, Dean P Phillips, John S Tyhonas, Charlotte Deckhut

Bioorg Med Chem Lett· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.
Mark D Leibowitz, Robert J Ardecky, Marcus F Boehm, Carol L Broderick, Mark A Carfagna, John S Tyhonas

Endocrinology· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
Pierre-Yves Michellys, Marcus F Boehm, Jyun-Hung Chen, Timothy A Grese, Donald S Karanewsky, John S Tyhonas

Bioorg Med Chem Lett· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
Pierre-Yves Michellys, Robert J Ardecky, Jyun-Hung Chen, Jennifer D'Arrigo, Timothy A Grese, John S Tyhonas

J Med Chem· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Garret J Etgen, Brian A Oldham, William T Johnson, Carol L Broderick, Chahrzad R Montrose, John S Tyhonas

Diabetes· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis